Optimal radiotherapy for prostate cancer: Predictions for conventional external beam, imrt, and brachytherapy from radiobiologic models

International Journal of Radiation Oncology Biology Physics

Volumn 46, Issue 1, 2000, Pages 165-172

  King, Christopher R ^a,b   DiPetrillo, Thomas A ^a,b   Wazer, David E ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Brachytherapy; Intensity modulation radiotherapy (IMRT); Prostate cancer; Radiobiology; Tumor control probability (TCP)

Indexed keywords

ARTICLE; BIOLOGICAL MODEL; BRACHYTHERAPY; CANCER CONTROL; CELL SURVIVAL; HIGH RISK POPULATION; HYPOXIA; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR;

ALGORITHMS; BRACHYTHERAPY; CELL HYPOXIA; CELL SURVIVAL; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; IODINE RADIOISOTOPES; LINEAR MODELS; MALE; MODELS, BIOLOGICAL; PALLADIUM; PROGNOSIS; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RADIOTHERAPY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RISK FACTORS; TUMOR CELLS, CULTURED;

EID: 0033957484     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00406-X     Document Type: Article

References (23)

1. Goitein M., Niemierko A. Intensity modulated therapy and inhomogeneous dose to the tumor a note of caution . Int. J. Radiat. Oncol. Biol. Phys. 36:1996;519-522.
2. Ling C.C., Roy J., Sahoo N., Wallner K., Anderson L. Quantifying the effect of dose inhomogeneity in brachytherapy application to permanent prostatic implant with I-125 seeds . Int. J. Radiat. Oncol. Biol. Phys. 28:1994;971-978.
3. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int. J. Radiat. Biol. Phys. 41:1998;491-500.
4. Dale R.G. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br. J. Radiol. 58:1985;515-528.
5. Dale R.G. Radiobiological assessment of permanent implants using tumor repopulation factors in the linear-quadratic model. Br. J. Radiol. 62:1989;241-244.
6. Nath R., Anderson L.L., Luxton G., Weaver K.A., Meigooni A. Dosimetry of interstitial brachytherapy sources recommendations of the AAPM Radiation Therapy Committee Task Force Group No. 43. Med . Phys. 22:1995;209-234.
7. Ling C.C., Li W.X., Anderson L.L. The relative biologic effectiveness of I-125 and Pd-103. Int. J. Radiat. Oncol. Biol. Phys. 32:1995;373-378.
8. Algan O., Stobbe C.C., Helt A.M., Hanks G.E., Chapman J.D. Radiation inactivation of human prostate cancer cells the role of apoptosis . Radiat. Res. 146:1996;267-275.
9. DeWeese T.L., Shipman J.M., Dillehay L.E., Nelson W.G. Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure. J. Urol. 159:1998;591-598.
10. Leith J.T., Quaranto L., Padfield G., Michelson S., Hercbergs A. Radiobiological studies of PC-3 and DU-145 human prostate cancer cells x-ray sensitivity in vitro and hypoxic fractions of xenografted tumors in vivo . Int. J. Radiat. Oncol. Biol. Phys. 25:1993;283-287.
11. Brenner D.J., Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 43:1999;1095-1101.
12. Duschesne G.M., Peters L.J. What is the α/β ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 44:1999;747-748.
13. Haustermans K.M.G., Hofland I., Van Poppel H., et al. Measurements in prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;1067-1070.
14. Movsas B., Chapman J.D., Horwitz E.M., et al. Toxic regions exist in human prostate carcinoma. Urology. 53:1999;11-18.
15. Rasey J.S., Koh W.-J., Evans M.L., et al. Quantifying regional hypoxia in human tumors with positron emission tomography of fluoromisonidazole a pretherapy study of 37 patients . Int. J. Radiat. Oncol. Biol. Phys. 36:1996;417-428.
16. Palcic B. In vivo and in vitro mechanisms of radiation sensitization, drug synthesis and screening can we learn it all from the high dose data? Int. J. Radiat. Oncol. Biol. Phys. 10:1984;1185-1193.
17. Ling C.C., Spiro I.J., Mitchell J., Stickler R. The variation of OER with dose rate. Int. J. Radiat. Oncol. Biol. Phys. 11:1985;1367-1373.
18. Brenner D.J., Hall E.J. Conditions for the equivalence of continuous to pulsed low dose rate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 20:1991;181-190.
19. Brenner D.J., Hall E.J., Youping H., Sachs R.K. Optimizing the time course of brachytherapy and other accelerated radiotherapeutic protocols. Int. J. Radiat. Oncol. Biol. Phys. 29:1994;893-901.
20. Blasko JC, Grimm PD, Sylvester J, Cavanagh W. Pd-103 and I-125 brachytherapy for prostate cancer. In: ASTRO Spring Refresher Course, 1999.
21. Shipley W.U., Thames H.D., Sandler H.M., et al. Radiation therapy for clinically localized prostate cancer a multi-institutional pooled analysis . JAMA. 281:1999;1598-1604.
22. Lee W.R., Hanks G.E., Corn B.W., Schultheiss T.E. Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 31:1995;21-24.
23. Schmid H.P. Tumour markers in patients on deferred treatment prostate specific antigen doubling times . Cancer Surv. 23:1995;157-167.